Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 998 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Comparison control condition Clear all

Conditions: Psychosis, Anxiety, Depression, Rumination
Interventions: Smartphone-based Mindfulness Exercise, Smartphone-based Psychoeducation, Neutral Control Message; Behavioral
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Hypertension
Interventions: Azilsartan medoxomil, Valsartan, Olmesartan, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 86
States / cities: Alabaster, Alabama • Ozark, Alabama • Green Valley, Arizona + 83 more

Conditions: Age-related Macular Degeneration
Interventions: Brolucizumab 6 mg, Aflibercept 2 mg; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 24
States / cities: Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more

Conditions: Diabetic Retinopathy
Interventions: Tarcocimab, Sham injection; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 38
States / cities: Tucson, Arizona • Fullerton, California • Glendale, California + 34 more

Conditions: Tumor Hyperinsulinism (Tumor HI)
Interventions: Ersodetug; Drug
Lead sponsor: Rezolute; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Chicago, Illinois • Bethesda, Maryland • Boston, Massachusetts + 5 more

Conditions: Major Depressive Disorder
Interventions: Tocilizumab; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Knowledge, Behavior
Interventions: STEPS2, STYH; Behavioral
Lead sponsor: City University of New York, School of Public Health; Other
Eligibility: 16 Years to 27 Years
Enrollment: 856 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Prevention, Control
Interventions: Mindfulness Program, Active Comparator; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 12 Years to 17 Years
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Evanston, Illinois • Nashville, Tennessee

Conditions: Aphasia
Interventions: Simultaneous music and reading lyrics, Priming with music, Control; Behavioral
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rocky Mount, Virginia

Conditions: Anxiety Disorder of Childhood
Interventions: Child Anxiety Learning Modules (CALM), Child Anxiety Learning Modules--Relaxation (CALM-R); Behavioral
Lead sponsor: UConn Health; Other
Eligibility: 5 Years to 12 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: West Hartford, Connecticut • Columbia, Maryland

Conditions: Obesity, Type 2 Diabetes
Interventions: VI-0521; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 2,487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 6
States / cities: Birmingham, Alabama • Ridgefield, Connecticut • New York, New York + 3 more

Conditions: Primary Progressive Aphasia
Interventions: Communication Bridge™, Evidence-Based Impairment Focused; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 100 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dry Eye
Interventions: Acoltremon 0.003%, Refresh classic preservative free; Drug
Lead sponsor: The Eye Care Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Communication, Health Behavior, Sedentary Lifestyle
Interventions: Computer-generated advisor, Comparison control condition; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 55 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol, Placebo to indacaterol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 54
States / cities: Anniston, Alabama • Jasper, Alabama • Glendale, Arizona + 46 more

Conditions: Alcohol Consumption
Interventions: Alcohol personalized normative feedback (APNF), Social media personalized normative feedback (SMPNF); Behavioral
Lead sponsor: Duquesne University; Other
Eligibility: 18 Years to 26 Years
Enrollment: 401 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Oxford, Ohio • Houston, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Gastric Cancer, Gastric Neoplasms, Gastric Adenocarcinoma
Interventions: Cellvizio (Registered trademark) Real-Time In Vivo Cellular Imaging Platform with Confocal Miniprobes, Olympus Graphics Interchange Format (GIF) 190 endoscope, Gastric mucosal biopsy; Device · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease
Interventions: Aes-103, Placebo; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Liver Diseases
Interventions: Uncertainty Management Intervention, Comparison Conditions for Liver Transplant; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 4
States / cities: Omaha, Nebraska • Chapel Hill, North Carolina • Durham, North Carolina + 1 more

Conditions: Alcohol Use, Drug Use, Diagnostic Self Evaluation, Gonorrhea, Unprotected Sex, Chlamydia, Trichomonas
Interventions: Project EMPWR, Optimized Standard Care (OSC); Behavioral · Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 49 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Fort Apache, Arizona

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Not listed
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bipolar I Disorder
Interventions: olanzapine, placebo, divalproex; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Hypercholesterolemia
Interventions: Praluent (Alirocumab), Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 2,176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 73
States / cities: Auburn, Alabama • Birmingham, Alabama • Mobile, Alabama + 63 more

Conditions: Breast Cancer
Interventions: Video and Booklet, Factsheet; Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Search by objective public record fields.

Pilot Study of Sensor-Informed Smartphone-based Mental Health Interventions for Mood in Early Psychosis

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

Neutralizing Interleukin (IL)-6

Socialization To Enrich Participation & Support Sexuality for Young People With I/DD

A Randomized Controlled Trial Testing the Effect of the Youth Mindful Awareness Program on Negative Affect (YMAP2).

Effect of Music on Reading Comprehension for Patients With Aphasia

Efficacy Trial of the CALM Intervention

Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions

Communication Bridge 2

Long-term Effects of Acoltremon vs. Control in Dry Eye Disease

Computer-Based Physical Activity Advice for Ethnic Minority Aging Adults

Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks

A Social Media Personalized Normative Feedback Intervention for Heavy Drinking College Students

Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

Uncertainty Management Intervention

Trial of an Adapted STD Screening and Risk Reduction Intervention

Developing New Ways to Detect Respiratory Impairment Early in ALS

A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Genetic Counseling for Breast Cancer Survivors (GC for BC)